➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
McKinsey
AstraZeneca
Johnson and Johnson
Boehringer Ingelheim

Last Updated: January 15, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208401

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 208401 describes QBRELIS, which is a drug marketed by Azurity and is included in one NDA. It is available from one supplier. There are six patents protecting this drug. Additional details are available on the QBRELIS profile page.

The generic ingredient in QBRELIS is lisinopril. There are twenty-one drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the lisinopril profile page.
Summary for 208401
Tradename:QBRELIS
Applicant:Azurity
Ingredient:lisinopril
Patents:6
Formulation / Manufacturing:see details
Pharmacology for NDA: 208401
Medical Subject Heading (MeSH) Categories for 208401
Suppliers and Packaging for NDA: 208401
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
QBRELIS lisinopril SOLUTION;ORAL 208401 NDA Azurity Pharmaceuticals, Inc. 52652-3001 52652-3001-1 150 mL in 1 BOTTLE (52652-3001-1)
Paragraph IV (Patent) Challenges for 208401
Tradename Dosage Ingredient NDA Submissiondate
QBRELIS SOLUTION;ORAL lisinopril 208401 2019-10-24

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrength1MG/ML
Approval Date:Jul 29, 2016TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Nov 6, 2035Product Flag?Substance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Nov 6, 2035Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Nov 6, 2035Product Flag?Substance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Johnson and Johnson
Express Scripts
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.